消癌解毒方联合FEC化疗对乳腺癌患者临床疗效的影响

详细信息    查看全文 | 推荐本文 |

英文篇名：Clinical Efficacy of Xiaoai Jiedu Formula Combined with FEC Chemotherapy on Breast Cancer Patients 作者：潘静云 ; 程海波 英文作者：PAN Jing-yun;CHENG Hai-bo;First Clinical Medical College,Nanjing University of Chinese Medicine,Jiangsu Collaborative Innovation Center of Tumors Prevention and Treatment with Traditional Chinese Medicine;Changzhou Wujin People's Hospital; 关键词：乳腺癌 ; 癌毒 ; 消癌解毒方 ; 柴胡疏肝散 ; 生脉饮 英文关键词：breast cancer;;carcinomas;;Xiaoai Jiedu formula;;Chaihu Shugan San;;Shengmaiyin 中文刊名：ZSFX 英文刊名：Chinese Journal of Experimental Traditional Medical Formulae 机构：南京中医药大学第一临床医学院江苏省中医药防治肿瘤协同创新中心;常州市武进人民医院; 出版日期：2018-11-05 10:27 出版单位：中国实验方剂学杂志 年：2019 期：v.25 基金：国家自然科学基金项目(81573910);; 国家重点研发计划项目(2017YFC1700602);; 江苏高校优势学科建设工程项目(PAPD) 语种：中文; 页：ZSFX201906014 页数：6 CN：06 ISSN：11-3495/R 分类号：103-108

摘要

目的:观察消癌解毒方联合氟尿嘧啶+表柔比星+环磷酰胺(5-FU+EPI+CTX,FEC)化疗方案对乳腺癌患者的免疫功能、肿瘤指标、中医证候积分、不良反应发生情况的影响。方法:将60例乳腺癌患者随机分为研究组和对照组,研究组进行FEC(CTX 0. 6 g·m~(-2),d1,EPI 100 mg·m~(-2),d1,5-FU 0. 5 g·m~(-2),d1)方案化疗,同时服用消癌解毒方制剂,连续服用2个周期,对照组单纯进行FEC方案化疗。2个周期后分析并比较两组的免疫功能、肿瘤指标、中医证候评分、不良反应发生情况的差异。结果:治疗前两组免疫指标相当,治疗后研究组免疫指标优于对照组(P <0. 05);治疗前两组患者癌胚抗原(CEA)和糖类抗原153(CA153)水平比较差异无统计学意义,与本组治疗前比较,治疗后两组CEA,CA153水平均明显下降,且研究组下降幅度更为明显(P <0. 05);两组治疗前胸胁不适、潮热盗汗、急躁易怒、口干口苦、睡眠积分比较差异无统计学意义,与本组治疗前比较,治疗后研究组中医证候积分低于对照组(P <0. 05);研究组患者不良反应发生率均低于对照组(P <0. 05)。结论:消癌解毒方联合FEC化疗能提高患者的免疫能力和临床疗效,改善患者的临床症状。
        Objective: To observe effect of Xiaoai Jiedu formula combined with fluorouracil( 5-FU) +epirubicin( EPI) + cyclophosphamide( CTX)( FEC) chemotherapy regimen on immune function,tumor index,traditional Chinese medicine( TCM) symptom scale score and adverse reactions of patients with breast cancer.Method: A total of 60 patients with breast cancer were randomly divided into study group and control group. FEC( CTX 0. 6 g·m~(-2),d1,EPI 100 mg·m~(-2),d1,5-FU 0. 5 g·m~(-2),d1) regimen was used in study group,and Xiaoai Jiedu formula recipe was used for two consecutive cycles. FEC regimen was used in control group only. After2 cycles,immunological changes,tumor index,TCM symptom score and adverse reactions were analyzed and compared between two groups. Result: There was not significant difference in immune indexes between two groups before treatment,but statistically significant differences after treatment( P < 0. 05). There was no statistically significant difference in levels of carcinoembryonic antigen( CEA) and carbohydrate antigen153( CA153)between two groups before treatment; CEA and CA153 levels significantly decreased in both groups,particularly in study group( P < 0. 05). There was no statistically significant difference in scores of fatigue,hot flashes and night sweats,irritability,dry mouth,appetite and sleep between two groups before treatment. The scores in study group were significantly lower than those in control group after treatment( P < 0. 05). The incidence of menstrual disorder,nausea,vomiting and constipation in study group was lower than that in control group( P < 0. 05).Conclusion: Xiaoai Jiedu formula combined with FEC chemotherapy can improve clinical efficacy and alleviate clinical symptoms of patients.

引文

[1]Jemal A,Bray F,Center M M,et al.Global cancer statistics[J].CA:A Cancer J Clin,2011,61(2):69-90.
    [2]王永川,魏丽娟,刘俊田,等.发达与发展中国家癌症发病率与死亡率的比较与分析[J].中国肿瘤临床,2012,39(10):679-682.
    [3]苏丽瑛,李仝,宋凤丽,等.中医药治疗乳腺癌内分泌综合征研究进展[J].辽宁中医药大学学报,2013,15(9):206-208.
    [4]周学平,叶放,郭立中,等.以病机为核心构建中医辨证论治新体系---国医大师周仲瑛教授学术思想探讨[J].中医杂志,2011,52(18):1531-1534.
    [5]程海波,吴勉华.周仲瑛教授“癌毒”学术思想探析[J].中华中医药杂志,2010,25(6):866-869.
    [6]陈四清,张成铭,叶丽红.消癌扶正法治疗肝癌介入后复发[J].江苏中医药,2007,39(2):42-43.
    [7]陈海彬,周红光,程海波,等.消癌解毒方对中晚期恶性肿瘤患者免疫功能的影响[J].南京医科大学学报:自然科学版,2009,29(9):1257-1259.
    [8]中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范[M].北京:北京医科大学、中国协和医科大学联合出版社,1991:1025-1029.
    [9]石学敏,戴锡孟,王键.中医内科学[M].北京:中国医药出版社,2009:404-405.
    [10]中华人民共和国卫生部.中国新药临床研究指导原则[M].北京:中国医药科技出版社,2002:288.
    [11]何光星,刘洁,王笳,等.中医药抗肿瘤作用机理研究现状[J].四川中医,2008,26(8):47-50.
    [12]李栋,程海波,周红光,等.“癌毒”学说内涵探讨及“消癌解毒方”抗癌生物学机制研究[J].辽宁中医杂志,2011,38(12):2360-2361.
    [13]陈四清.周仲瑛教授从癌毒辨治肿瘤经验[J].新中医,2004,36(2):7-9.
    [14]叶丽红,顾勤.周仲瑛教授的肿瘤观[J].中国中医药信息杂志,2002,9(3):63-64.
    [15]程海波,吴勉华.周仲瑛教授从癌毒辨治恶性肿瘤病机要素分析[J].中华中医药学刊,2010,28(2):313-316.
    [16]张星星,吴坚,李东,等.白毛夏枯草提取液抗肝癌体内外实验研究[J].辽宁中医药大学学报,2013,12(15):58-60.
    [17]关频,王建农.天葵子化学成分和抗肿瘤活性的初步研究[J].时珍国医国药,2011,22(1):255-256.
    [18]张瑜.八月札抗肿瘤作用的初步研究[J].广西中医药大学学报,2016,19(3):9-10.
    [19]金爱花,许惠仙,刘文静,等.祁州漏芦对H22小鼠肝癌皮下移植瘤的抑瘤作用及其机制初探[J].中国实验方剂学杂志,2011,17(5):165-167.
    [20]蔡晶,李孝栋,陈旭征,等.太子参多糖粗提物对小鼠免疫功能的影响[J].福建中医学院学报,2005,15(3):33-35.
    [21]高承贤,丁志山,尹丽慧,等.参麦注射液对移植性肿瘤血管生成的影响[J].中成药,2003,25(9):728-731.
    [22]刘丹,王佳贺.柴胡皂苷抗肿瘤作用机制研究进展[J].现代药物与临床,2018,3(1):203-208.
    [23]方国英,王天勇,白云霞.香附有效成分的提取及其抗肿瘤药效的实验研究[J].中华危重症医学杂志,2015,8(4):261-263.
    [24]李黎,王明艳,陈海彬,等.消癌解毒方含药血清对人肝癌SMMC-7721细胞的抑制作用[J].中药新药与临床药理,2011,22(6):587-589.
    [25]张玉,吴勉华,陈海彬,等.消癌解毒方体内抑瘤作用机制研究[J].中国实验方剂学杂志,2011,17(11):234-237.
    [26]李黎,沈波,陈海彬,等.消癌解毒方对H22荷瘤小鼠外周血清转化生长因子β1的影响[J].辽宁中医杂志,2011,38(11):2283-2284.
    [27]石文静,谭佳妮,沈卫星,等.消癌解毒方对CT26荷瘤小鼠IL-6/STAT3信号通路的影响[J].辽宁中医杂志,2018,45(6):1289-1292.
    [28]马艳霞,李黎,吴勉华,等.消癌解毒方对H22荷瘤小鼠移植瘤的抗肿瘤作用机制[J].中国实验方剂学杂志,2018,24(23):1-6.
    [29]杨静,陈海彬,周红光,等.消癌解毒方干预W256移植瘤大鼠的血浆代谢组学分析[J].中国实验方剂学杂志,2015,21(23):77-82.
    [30]孙浩,沈卫星,徐长亮,等.消癌解毒方联合顺铂通过调控组蛋白去甲基化酶抑制4T1荷瘤小鼠肿瘤生长[J].中国实验方剂学杂志,2018,24(13):78-84.
    [31]孙浩,沈卫星,徐长亮,等.消癌解毒方通过调控PI3K/AKT通路抑制乳腺癌细胞株MDA-MB-231增殖的作用与机制探讨[J].南京中医药大学学报,2018,3(34):173-177.
    [32]林文棠,朱平.实用临床免疫学[M].西安:第四军医大学出版社,2003:161-173.
    [33]梁超,张胜华,蔡照弟,等.早期肠内应用四君子汤对消化道肿瘤术后患者免疫功能的影响[J].中国中西医结合杂志,2005,25(12):1070-1073.
    [34]Gilboa E.DC-based cancer vaccines[J].J Clin Invest,2007,117(5):1195-1203
    [35]何维.医学免疫学[M].2版.北京:人民卫生出版社,2010:342.